bluebird bio, Inc. (NASDAQ:BLUE) COO Susanna Gatti High sold 1,282 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $172.15, for a total transaction of $220,696.30. Following the completion of the transaction, the chief operating officer now directly owns 13,718 shares of the company’s stock, valued at approximately $2,361,553.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded up $0.35 during mid-day trading on Tuesday, reaching $162.65. 563,699 shares of the company’s stock were exchanged, compared to its average volume of 825,312. bluebird bio, Inc. has a 12-month low of $60.95 and a 12-month high of $174.65.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). The firm had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business’s revenue was up 397.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.07) EPS. equities research analysts expect that bluebird bio, Inc. will post -6.68 EPS for the current year.

A number of research firms recently weighed in on BLUE. Canaccord Genuity began coverage on shares of bluebird bio in a research report on Tuesday. They issued a “buy” rating and a $202.00 target price for the company. BidaskClub raised shares of bluebird bio from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Evercore ISI began coverage on shares of bluebird bio in a research report on Wednesday, August 16th. They issued an “in-line” rating and a $102.00 target price for the company. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $158.00 target price (up previously from $134.00) on shares of bluebird bio in a research report on Tuesday, September 5th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $170.00 target price (up previously from $100.00) on shares of bluebird bio in a research report on Monday, October 9th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $137.57.

Several hedge funds and other institutional investors have recently bought and sold shares of BLUE. FMR LLC lifted its stake in shares of bluebird bio by 9.6% during the 2nd quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock worth $705,301,000 after buying an additional 587,236 shares during the last quarter. Capital Research Global Investors lifted its stake in shares of bluebird bio by 9.9% during the 2nd quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock worth $576,001,000 after buying an additional 493,072 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of bluebird bio by 10.7% during the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock worth $373,884,000 after buying an additional 343,856 shares during the last quarter. Eagle Asset Management Inc. acquired a new stake in shares of bluebird bio during the 3rd quarter worth about $29,539,000. Finally, American Century Companies Inc. acquired a new stake in shares of bluebird bio during the 3rd quarter worth about $31,170,000.

COPYRIGHT VIOLATION WARNING: “bluebird bio, Inc. (BLUE) COO Sells $220,696.30 in Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/05/bluebird-bio-inc-blue-coo-sells-220696-30-in-stock.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.